DIRS.INFO The most relevant business & tech news

☆ Roche enters obesity market with Carmot takeover but drugs may not be available until 2030
▼ + stars: | 2023-12-04 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

BRAZIL - 2021/11/26: In this photo illustration a F. HoffmannLa Roche AG logo is seen on a screen and a hand holding a pill. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)Swiss pharmaceuticals giant Roche is set to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest company to attempt to unseat Novo Nordisk and Eli Lilly's dominance within the global weight-loss drugs market. The U.S. takeover target's early-stage technology could help crack highly prized oral obesity treatments, Roche Pharmaceuticals CEO Teresa Graham said Monday, but it may be several years before the drugs are widely available. The deal will provide Roche access to Carmot's current research and development portfolio, including all clinical and preclinical assets. Shares of the Swiss company, which have been in the doldrums this year, were up 2.25% following the news of the acquisition.

Persons: HoffmannLa Roche, Rafael Henrique, Roche, Eli Lilly's, Teresa Graham, we'll, Graham, CNBC's Julianna Tatelbaum, Eli Lilly's Mounjaro Organizations: Getty Images, Carmot Therapeutics, Novo Nordisk, U.S, Roche Pharmaceuticals, Roche Locations: BRAZIL, Swiss, California

☆ A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
▼ + stars: | 2023-10-24 | by ( Filip De Mott | ) www.businessinsider.com time to read: +4 min

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.

Persons: Roche, Roivant, —, Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan

☆ Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings
▼ + stars: | 2023-10-23 | by ( Hannah Ward-Glenton | ) www.cnbc.com time to read: +1 min

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction. Telavant produces drugs for people suffering from inflammatory and fibrotic diseases and is in the process of developing a "promising new therapy" for patients with Crohn's disease, Roche said in a press release. "We are eager to develop this antibody further and bring it to market and patients in the US and Japan as soon as possible." Telavant is currently owned by Pfizer and Roivant Sciences. In the Monday announcement, Roche also said it would obtain an option to collaborate with Pfizer on a new inflammatory bowel disease drug.

Persons: Roche, — Roche, Teresa Graham, Telavant Organizations: Monday, Telavant Holdings, Roche Pharmaceuticals, CNBC, Pfizer, Roivant Sciences Locations: Japan

☆ Roche flags 2023 earnings decline on slump in COVID products
▼ + stars: | 2023-02-02 | by ( Ludwig Burger | ) www.reuters.com time to read: +1 min

Last year, group revenue edged 1% higher to 63.3 billion Swiss francs ($69.78 billion), the company reported, beating market expectations of 63.2 billion francs, while core operating profit gained 1% to 22.2 billion Swiss francs, just shy of the average analyst estimate of 22.4 billion francs. The onus to reinvigorate the pipeline will be on chief executive officer-designate Thomas Schinecker, who is Roche's head of diagnostics, and due to be promoted to group CEO in March. In the wake of Schinecker's appointment, the head of Roche's pharmaceuticals division, Bill Anderson, decided in December to leave after 16 years with the Swiss drugmaker. Roche said on Thursday that Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, would succeed Anderson. ($1 = 0.9071 Swiss francs)Reporting by Ludwig Burger; Editing by Paul Carrel and Rashmi AichOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Teresa Graham"

4 mentions found